# Generation of Functionally Competent Human Mast Cells from Limited Blood Volumes

**Authors:** Sanne J. van de Meerendonk, Michelle du Toit, Vincent H. J. van der Velden, P. Martin van Hagen, Paul L. A. van Daele, Astrid G. S. van Halteren, Willem A. Dik

PMC · DOI: 10.3390/ijms27041793 · International Journal of Molecular Sciences · 2026-02-13

## TL;DR

This study presents a new method to generate functional human mast cells from small blood samples, which could improve research and clinical applications.

## Contribution

A novel protocol for generating mast cells from limited blood volumes, enabling efficient in vitro production.

## Key findings

- Mast cells generated from small blood volumes showed comparable granule and receptor expression to those from buffy coat-derived cells.
- The generated mast cells responded to standard activating agents like IgE/anti-IgE and C48/80.
- The protocol maintains functional competence despite a 12-week in vitro culture period.

## Abstract

Mast cells (MCs) are innate immune cells that are derived from CD34+ hematopoietic stem/progenitor cells (HSPCs) and mature in peripheral tissues such as skin and mucosa. Mature human MCs can be generated from peripheral blood, but this process requires substantial blood volumes as HSPC frequencies are typically very low. The aim of this study was to validate a new in-house-developed protocol for the generation of MCs from less than 20 mL of peripheral blood. To this end, we used a magnetic bead-based procedure to isolate ‘untouched’ HSPCs from 14 to 16 mL peripheral blood (PB). In total, 12 cultures were set up with blood from seven healthy donors, wherein HSPCs were first expanded for 4 weeks, followed by another 8 weeks of culture in MC maturation-inducing medium. Flowcytometric analysis, histochemical staining, and degranulation assays were used to assess their phenotypic and functional features. Our data show comparable expression of cytoplasmic granules and cell-surface expression of MRGPRX2, FcεR1α, and CD117 in 8/12 blood-derived MCs (PB-MCs) and buffy coat-derived HSPCs (BC-MCs). PB-MCs responded to classic stimulating agents like IgE/anti-IgE and C48/80. Hence, our novel MC generation protocol yields functionally competent MCs with no compromise in their maturation or activation potential despite 12 weeks of in vitro culture.

## Linked entities

- **Proteins:** MRGPRX2 (MAS related GPR family member X2), FCER1A (Fc epsilon receptor Ia), KIT (KIT proto-oncogene, receptor tyrosine kinase)
- **Chemicals:** IgE (PubChem CID 19920), C48/80 (PubChem CID 104735)

## Full-text entities

- **Genes:** CD40 (CD40 molecule) [NCBI Gene 958] {aka Bp50, CDW40, TNFRSF5, p50}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, KIT (KIT proto-oncogene, receptor tyrosine kinase) [NCBI Gene 3815] {aka C-Kit, CD117, MASTC, PBT, SCFR}, CD14 (CD14 molecule) [NCBI Gene 929], CD69 (CD69 molecule) [NCBI Gene 969] {aka AIM, BL-AC/P26, CLEC2C, EA1, GP32/28, MLR-3}, FCGR3A (Fc gamma receptor IIIa) [NCBI Gene 2214] {aka CD16-II, CD16A, FCG3, FCGR3, FCRIIIA, FcGRIIIA}, TFRC (transferrin receptor) [NCBI Gene 7037] {aka CD71, IMD46, T9, TFR, TFR1, TR}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, TNFRSF8 (TNF receptor superfamily member 8) [NCBI Gene 943] {aka CD30, D1S166E, Ki-1}, IL3 (interleukin 3) [NCBI Gene 3562] {aka IL-3, MCGF, MULTI-CSF}, CD33 (CD33 molecule) [NCBI Gene 945] {aka CD33rSiglec, SIGLEC-3, SIGLEC3, p67}, FUT4 (fucosyltransferase 4) [NCBI Gene 2526] {aka CD15, ELFT, FCT3A, FUC-TIV, FUTIV, LeX}, IL3RA (interleukin 3 receptor subunit alpha) [NCBI Gene 3563] {aka CD123, IL-3R-alpha, IL3R, IL3RAY, IL3RX, IL3RY}, FCER1A (Fc epsilon receptor Ia) [NCBI Gene 2205] {aka FCE1A, FCERIA, FcERI}, CXCR6 (C-X-C motif chemokine receptor 6) [NCBI Gene 10663] {aka BONZO, CD186, CDw186, STRL33, TYMSTR}, CD19 (CD19 molecule) [NCBI Gene 930] {aka B4, CVID3}, GYPA (glycophorin A (MNS blood group)) [NCBI Gene 2993] {aka CD235a, GPA, GPErik, GPSAT, HGpMiV, HGpMiXI}, OGA (O-GlcNAcase) [NCBI Gene 10724] {aka MEA5, MGEA5, NCOAT}, ITGAM (integrin subunit alpha M) [NCBI Gene 3684] {aka CD11B, CR3A, HNA-4, MAC-1, MAC1A, MO1A}, CD38 (CD38 molecule) [NCBI Gene 952] {aka ADPRC 1, ADPRC1, cADPR1}, NCAM1 (neural cell adhesion molecule 1) [NCBI Gene 4684] {aka CD56, MSK39, NCAM}, MRGPRX2 (MAS related GPR family member X2) [NCBI Gene 117194] {aka MGRG3, MRGX2}, CD2 (CD2 molecule) [NCBI Gene 914] {aka LFA-2, SRBC, T11}, CD9 (CD9 molecule) [NCBI Gene 928] {aka BTCC-1, DRAP-27, MIC3, MRP-1, TSPAN-29, TSPAN29}, IGHE (immunoglobulin heavy constant epsilon) [NCBI Gene 3497] {aka IgE}, CD63 (CD63 molecule) [NCBI Gene 967] {aka AD1, HOP-26, ME491, MLA1, OMA81H, Pltgp40}, PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}, IL2RA (interleukin 2 receptor subunit alpha) [NCBI Gene 3559] {aka CD25, IDDM10, IL2R, IMD41, TCGFR, p55}, ANPEP (alanyl aminopeptidase, membrane) [NCBI Gene 290] {aka AP-M, AP-N, APN, CD13, GP150, LAP1}, KITLG (KIT ligand) [NCBI Gene 4254] {aka DCUA, DFNA69, FPH2, FPHH, KL-1, Kitl}, CD34 (CD34 molecule) [NCBI Gene 947]
- **Diseases:** cardiovascular disease (MESH:D002318), MC activation (OMIM:612348), metastasis (MESH:D009362), rheumatoid arthritis (MESH:D001172), tissue damage (MESH:D017695), allergic and (MESH:D004342), type 1 diabetes (MESH:D003922), cancer (MESH:D009369), neuroinflammation (MESH:D000090862), inflammation (MESH:D007249), neurodegenerative disease (MESH:D019636), injury to (MESH:D014947), mastocytosis (MESH:D008415), fibrosis (MESH:D005355), MC disorders (MESH:D009358), systemic lupus erythematosus (MESH:D008180), systemic mastocytosis (MESH:D034721), autoimmune disease (MESH:D001327), atopic disorders (MESH:D006969)
- **Chemicals:** compound 48/80 (MESH:D003189), C48/80 (-), glycerin (MESH:D005990), PBS (MESH:D007854), A23187 (MESH:D000001), sodium-heparin (MESH:D006493), calcium (MESH:D002118), 4-MUG (MESH:C025158), polystyrene (MESH:D011137), lipid (MESH:D008055), EDTA (MESH:D004492), 7-AAD (MESH:C025942), CaCl2 (MESH:D002122), biotin (MESH:D001710), toluidine blue (MESH:D014048), glycine (MESH:D005998), sodium azide (MESH:D019810)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** p.D816V
- **Cell lines:** LAD2 — Homo sapiens (Human), Factor-dependent cell line (CVCL_0387), HMC-1 — Homo sapiens (Human), Mast cell leukemia, Cancer cell line (CVCL_0003), S2 — Drosophila melanogaster (Fruit fly), Spontaneously immortalized cell line (CVCL_Z232)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12940524/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12940524/full.md

## References

49 references — full list in the complete paper: https://tomesphere.com/paper/PMC12940524/full.md

---
Source: https://tomesphere.com/paper/PMC12940524